How High Can Palantir Stock Go?
Palantir Technologies (NASDAQ:PLTR) has been one of the undisputed victors…
Sell
32
TECH Quote, Financials, Valuation and Earnings
Last price:
$73.83
Seasonality move
:
3.21%
Day range:
$70.76 - $74.06
52-week range:
$61.16 - $85.57
Dividend yield:
0.43%
P/E ratio:
78.50x
P/S ratio:
10.11x
P/B ratio:
5.48x
Volume:
656.6K
Avg. volume:
752.8K
1-year change:
2.29%
Market cap:
$11.7B
Revenue:
$1.2B
EPS (TTM):
$0.94
Analysts' Opinion
-
Consensus RatingBio-Techne has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $81.38, Bio-Techne has an estimated upside of 15.55% from its current price of $73.79.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $65.00 representing 100% downside risk from its current price of $73.79.
Fair Value
-
According to the consensus of 12 analysts, Bio-Techne has 15.55% upside to fair value with a price target of $81.38 per share.
TECH vs. S&P 500
-
Over the past 5 trading days, Bio-Techne has overperformed the S&P 500 by 1.27% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bio-Techne does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bio-Techne has grown year-over-year revenues for 17 quarters straight. In the most recent quarter Bio-Techne reported revenues of $289.5M.
Earnings Growth
-
Bio-Techne earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Bio-Techne reported earnings per share of $0.21.
Enterprise value:
11.8B
EV / Invested capital:
--
Price / LTM sales:
10.11x
EV / EBIT:
62.52x
EV / Revenue:
10.10x
PEG ratio (5yr expected):
--
EV / Free cash flow:
48.31x
Price / Operating cash flow:
48.36x
Enterprise value / EBITDA:
39.37x
Gross Profit (TTM):
$767.6M
Return On Assets:
5.52%
Net Income Margin (TTM):
12.86%
Return On Equity:
7.4%
Return On Invested Capital:
6.24%
Operating Margin:
13.81%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.1B | $1.1B | $1.2B | $276.9M | $289.5M | |
| Gross Profit | $765.1M | $775.4M | $767.6M | $185.2M | $183M | |
| Operating Income | $288.9M | $290.5M | $227M | $55.9M | $40M | |
| EBITDA | $452.4M | $406M | $300.6M | $83M | $70.5M | |
| Diluted EPS | $1.79 | $1.52 | $0.94 | $0.31 | $0.21 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $541.9M | $543.7M | $552M | $591.5M | $648.6M | |
| Total Assets | $2.1B | $2.3B | $2.4B | $2.8B | $2.7B | |
| Current Liabilities | $105.4M | $134M | $137.6M | $127.8M | $142.1M | |
| Total Liabilities | $613.8M | $623.2M | $599.6M | $757.6M | $597.4M | |
| Total Equity | $1.4B | $1.6B | $1.8B | $2B | $2.1B | |
| Total Debt | $323.6M | $300.2M | $264.7M | $440M | $300M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $332.9M | $257.7M | $303.5M | $59.4M | $63.9M | |
| Cash From Investing | -$109.4M | -$400.1M | -$70.6M | -$154.1M | -$21.7M | |
| Cash From Financing | -$235M | $125.9M | -$205.5M | $71.5M | -$11.6M | |
| Free Cash Flow | $284.5M | $215.4M | $245M | $45.8M | $54.7M | |
TECH
Sector
Market Cap
$11.7B
$49.2M
Price % of 52-Week High
86.23%
48.57%
Dividend Yield
0.43%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
2.29%
-30.94%
Beta (5-Year)
1.270
0.754
Dividend yield:
0.43%
Annualized payout:
$0.32
Payout ratio:
33.48%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$72.69
200-day SMA
Sell
Level
$73.92
Bollinger Bands (100)
Buy
Level
70.99 - 76.45
Chaikin Money Flow
Buy
Level
71.9M
20-day SMA
Sell
Level
$74.05
Relative Strength Index (RSI14)
Buy
Level
51.14
ADX Line
Buy
Level
9.54
Williams %R
Neutral
Level
-47.0516
50-day SMA
Buy
Level
$73.43
MACD (12, 26)
Sell
Level
-0.42
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
29.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (12.275)
Buy
CA Score
(Annual)
Level (1.217)
Buy
Beneish M-Score
(Annual)
Level (-2.6023)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-2.2019)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Stock Forecast FAQ
In the current month, TECH has received 9 Buy ratings 3 Hold ratings, and 0 Sell ratings. The TECH average analyst price target in the past 3 months is $81.38.
-
Where Will Bio-Techne Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bio-Techne share price will rise to $81.38 per share over the next 12 months.
-
What Do Analysts Say About Bio-Techne?
Analysts are divided on their view about Bio-Techne share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bio-Techne is a Sell and believe this share price will drop from its current level to $65.00.
-
What Is Bio-Techne's Price Target?
The price target for Bio-Techne over the next 1-year time period is forecast to be $81.38 according to 12 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is TECH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bio-Techne is a Buy. 9 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TECH?
You can purchase shares of Bio-Techne via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bio-Techne shares.
-
What Is The Bio-Techne Share Price Today?
Bio-Techne was last trading at $73.83 per share. This represents the most recent stock quote for Bio-Techne. Yesterday, Bio-Techne closed at $73.79 per share.
-
How To Buy Bio-Techne Stock Online?
In order to purchase Bio-Techne stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will This ETF Beat the Market Over the Next 12 Months?
2024 was another banner year for the US stock market,…
Why Did Carlos Slim Buy PBF Energy?
Carlos Slim made a splash in a surprising sector last…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
